NEW YORK, Sept. 25, 2013 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of AMAG Pharmaceuticals, Inc. ("AMAG Pharmaceuticals" or the "Company") (NasdaqGS: AMAG).  The investigation focuses on whether the Company and its executives complied with federal securities laws.

On September 25, 2013, shares of AMAG Pharmaceuticals fell $3.53 or 13.49% during intraday trading to trade at $22.63 after the company disclosed in a regulatory filing that it had received a notification from the FDA in connection with the Company's supplemental New Drug Application for its Feraheme Injection on September 23, 2013.  The FDA stated, "that, as part of its ongoing review of the Company's sNDA, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments by September 23, 2013, a target date previously communicated by the FDA in a letter dated March 5, 2013."  

If you are aware of any facts relating to this investigation, or purchased shares of AMAG Pharmaceuticals, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.  Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein 212-697-6484info@bgandg.com

 

SOURCE Bronstein, Gewirtz & Grossman, LLC

RELATED LINKShttp://www.bgandg.com